<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01785069</url>
  </required_header>
  <id_info>
    <org_study_id>410XL-001</org_study_id>
    <nct_id>NCT01785069</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-filled X-Style and L-Style Breast Implants</brief_title>
  <official_title>A Prospective Multicenter Study of the Safety and Effectiveness of NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-filled X-style and L-style Breast Implants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter study of the safety and effectiveness of NATRELLE® 410
      Highly Cohesive, Anatomically Shaped, Silicone-Filled X-Style and L-Style Breast Implants.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    There was no indication that long-term follow-up would differ between any of the studies that
    have evaluated devices within the 410 Style Matrix.
  </why_stopped>
  <start_date type="Actual">December 10, 2012</start_date>
  <completion_date type="Actual">November 30, 2015</completion_date>
  <primary_completion_date type="Actual">November 30, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants According to Investigator Satisfaction With Implants</measure>
    <time_frame>3 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
    <description>The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied,3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants According to Participant Satisfaction With Implants</measure>
    <time_frame>3 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
    <description>The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Local Complications</measure>
    <time_frame>5 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
    <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast Pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Implant malposition, Implant palpability/visibility. Implant rupture, Infection, Ptosis, Redness, Swelling, Wrinkling/rippling and Other complications (calcifications on mammogram, thing of mastectomy flap, deformity and nipple stretching).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Reoperations</measure>
    <time_frame>5 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
    <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Implant Removal With or Without Replacement</measure>
    <time_frame>5 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
    <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Breast Augmentation</condition>
  <condition>Breast Reconstruction</condition>
  <condition>Breast Implant Revision</condition>
  <arm_group>
    <arm_group_label>Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revision-Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revision-Reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection</intervention_name>
    <description>Surgical implant</description>
    <arm_group_label>Augmentation</arm_group_label>
    <arm_group_label>Reconstruction</arm_group_label>
    <arm_group_label>Revision-Augmentation</arm_group_label>
    <arm_group_label>Revision-Reconstruction</arm_group_label>
    <other_name>NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-Filled Breast Implants</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For entry in this study, participants must have been enrolled in the 410 Continued Access
        (CA) Clinical Study or 410 Continued Access Reconstruction/Revision Expansion (CARE)
        Clinical Study under the inclusion criteria listed below and received NATRELLE® 410 Highly
        Cohesive, Anatomically Shaped, Silicone-Filled X-Styles or L-Styles breast implants

          -  Female, age 18 or older

          -  Present with 1 or more of the following conditions:

               1. Primary breast augmentation (i.e., no previous breast implant surgery) indicated
                  for subject dissatisfaction with size or shape of breast (e.g., mammary
                  hypoplasia), asymmetry, ptosis, or aplasia

               2. Primary breast reconstruction (i.e., no previous breast implant surgery other
                  than implantation of tissue expanders or contralateral augmentation for
                  asymmetry) indicated, in the affected breast, for mastectomy for cancer,
                  prophylactic mastectomy, or breast trauma (resulting in mastectomy) and for the
                  unaffected breast, contralateral asymmetry (may be performed on the date of the
                  mastectomy or the date when the permanent implants are placed in the
                  reconstructed breast)

               3. Breast implant revision surgery (i.e., removal and replacement of breast
                  implants) indicated for previous augmentation or reconstruction with
                  silicone-filled or saline-filled breast implants

          -  Has adequate tissue available to cover implants

          -  Willing to undergo magnetic resonance imaging (MRI) at the specified follow-up visits
             for subjects at MRI designated sites and be eligible for MRI (e.g., no implanted metal
             or metal devices, no history of severe claustrophobia)

        Exclusion Criteria:

        For entry in this study, participants must have been enrolled in the 410 CA Clinical Study
        or 410 CARE Clinical Study, meeting the exclusion criteria listed below, did not receive
        any NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-Filled FM, FF, MM, or MF
        Style Breast Implants, and have not undergone implant removal with or without replacement
        surgery

          -  Does not have advance fibrocystic disease considered to be premalignant without
             accompanying subcutaneous mastectomy

          -  Does not have existing carcinoma of the breast, without mastectomy

          -  Does not have abscess or infection in the body at the time of enrollment

          -  Is not pregnant or nursing

          -  Does not have any disease, including uncontrolled diabetes (e.g., hemoglobin A1c
             (HbA1c) &gt; 8%), that is clinically known to impact wound healing ability

          -  Does not show tissue characteristics that are clinically incompatible with
             mammaplasty, such as tissue damage resulting from radiation inadequate tissue,
             compromised vascularity, or ulceration

          -  Does not have or is under treatment for any condition that may constitute an
             unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems)

          -  Does not show psychological characteristics that may be incompatible with the surgical
             procedure and the prosthesis, such as inappropriate attitude or motivation (e.g., body
             dysmorphic disorder)

          -  Is not willing to undergo further surgery for revision, if medically required
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Schumacher</last_name>
    <role>Study Chair</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laurence Berkowitz</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roy Hong</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eric Bachelor</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gregory Liebscher</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott Spear</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvin Peters</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Erhardt</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Namnoum</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janet Turkle</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julene Samuels</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timothy Mickel</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Renucci</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Morris</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Nathan</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herluf Jr. Lund</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patricia McGuire</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perry Johnson</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Hyans</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Hetzler</name>
      <address>
        <city>Little Silver</city>
        <state>New Jersey</state>
        <zip>07739</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caroline Glicksman</name>
      <address>
        <city>Sea Girt</city>
        <state>New Jersey</state>
        <zip>08750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tracy Pfeifer</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lloyd Gayle</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raymond Isakov</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Craig Colville</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank Barone</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Gingrass</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patrick Maxwell</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey Friedman</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Blanchard</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>February 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <results_first_submitted>May 13, 2020</results_first_submitted>
  <results_first_submitted_qc>June 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2020</results_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Augmentation</title>
          <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="P2">
          <title>Revision-Augmentation</title>
          <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="P3">
          <title>Reconstruction</title>
          <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="P4">
          <title>Revision-Reconstruction</title>
          <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Implanted with nonstudy device</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject choice</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not evaluable</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Evaluable population was defined as all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and magnetic resonance imaging (MRI) within the window.</population>
      <group_list>
        <group group_id="B1">
          <title>Augmentation</title>
          <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="B2">
          <title>Revision-Augmentation</title>
          <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="B3">
          <title>Reconstruction</title>
          <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="B4">
          <title>Revision-Reconstruction</title>
          <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="60"/>
            <count group_id="B5" value="331"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" lower_limit="19.0" upper_limit="60.0"/>
                    <measurement group_id="B2" value="48.3" lower_limit="26.0" upper_limit="68.0"/>
                    <measurement group_id="B3" value="51.8" lower_limit="28.0" upper_limit="69.0"/>
                    <measurement group_id="B4" value="54.7" lower_limit="25.0" upper_limit="71.0"/>
                    <measurement group_id="B5" value="46.5" lower_limit="19.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="331"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants According to Investigator Satisfaction With Implants</title>
        <description>The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied,3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
        <time_frame>3 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
        <population>Participants from the Evaluable population, all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants According to Investigator Satisfaction With Implants</title>
          <description>The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied,3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
          <population>Participants from the Evaluable population, all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0"/>
                    <measurement group_id="O2" value="97.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants According to Participant Satisfaction With Implants</title>
        <description>The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
        <time_frame>3 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
        <population>Participants from the Evaluable population, all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants According to Participant Satisfaction With Implants</title>
          <description>The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
          <population>Participants from the Evaluable population, all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0"/>
                    <measurement group_id="O2" value="95.5"/>
                    <measurement group_id="O3" value="94.9"/>
                    <measurement group_id="O4" value="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Local Complications</title>
        <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast Pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Implant malposition, Implant palpability/visibility. Implant rupture, Infection, Ptosis, Redness, Swelling, Wrinkling/rippling and Other complications (calcifications on mammogram, thing of mastectomy flap, deformity and nipple stretching).</description>
        <time_frame>5 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
        <population>Evaluable population was defined as all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Local Complications</title>
          <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast Pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Implant malposition, Implant palpability/visibility. Implant rupture, Infection, Ptosis, Redness, Swelling, Wrinkling/rippling and Other complications (calcifications on mammogram, thing of mastectomy flap, deformity and nipple stretching).</description>
          <population>Evaluable population was defined as all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.05" lower_limit="4.81" upper_limit="16.66"/>
                    <measurement group_id="O2" value="15.71" lower_limit="9.03" upper_limit="26.58"/>
                    <measurement group_id="O3" value="15.28" lower_limit="9.34" upper_limit="24.43"/>
                    <measurement group_id="O4" value="3.77" lower_limit="0.95" upper_limit="14.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymmetry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.14" upper_limit="6.89"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="3.03" lower_limit="0.99" upper_limit="9.10"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.50" upper_limit="7.76"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.14" upper_limit="6.95"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.28" upper_limit="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capsular contracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="0.99" upper_limit="9.17"/>
                    <measurement group_id="O2" value="3.12" lower_limit="0.78" upper_limit="12.01"/>
                    <measurement group_id="O3" value="4.40" lower_limit="1.67" upper_limit="11.34"/>
                    <measurement group_id="O4" value="3.67" lower_limit="0.93" upper_limit="13.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed wound healing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.20" upper_limit="9.45"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluid accumulation/seroma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.20" upper_limit="9.45"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implant malposition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.98" upper_limit="9.01"/>
                    <measurement group_id="O2" value="4.17" lower_limit="1.36" upper_limit="12.36"/>
                    <measurement group_id="O3" value="4.04" lower_limit="1.54" upper_limit="10.41"/>
                    <measurement group_id="O4" value="1.67" lower_limit="0.24" upper_limit="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implant palpability/visibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.20" upper_limit="9.45"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implant rupture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="1.01" upper_limit="9.29"/>
                    <measurement group_id="O2" value="12.64" lower_limit="5.12" upper_limit="29.38"/>
                    <measurement group_id="O3" value="2.16" lower_limit="0.55" upper_limit="8.38"/>
                    <measurement group_id="O4" value="5.91" lower_limit="1.91" upper_limit="16.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.20" upper_limit="9.45"/>
                    <measurement group_id="O3" value="2.02" lower_limit="0.51" upper_limit="7.84"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ptosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.20" upper_limit="9.45"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.14" upper_limit="6.89"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="2.02" lower_limit="0.51" upper_limit="7.84"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.15" upper_limit="7.24"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wrinkling/rippling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="2.78" lower_limit="0.70" upper_limit="10.65"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="1.67" lower_limit="0.24" upper_limit="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.14" upper_limit="6.89"/>
                    <measurement group_id="O2" value="2.78" lower_limit="0.70" upper_limit="10.65"/>
                    <measurement group_id="O3" value="2.12" lower_limit="0.53" upper_limit="8.22"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Reoperations</title>
        <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.</description>
        <time_frame>5 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
        <population>Evaluable population was defined as all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reoperations</title>
          <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.</description>
          <population>Evaluable population was defined as all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.07" lower_limit="4.82" upper_limit="16.71"/>
                    <measurement group_id="O2" value="25.64" lower_limit="16.44" upper_limit="38.66"/>
                    <measurement group_id="O3" value="39.84" lower_limit="30.88" upper_limit="50.30"/>
                    <measurement group_id="O4" value="39.01" lower_limit="27.81" upper_limit="52.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Implant Removal With or Without Replacement</title>
        <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement</description>
        <time_frame>5 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
        <population>Evaluable population was defined as all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Implant Removal With or Without Replacement</title>
          <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement</description>
          <population>Evaluable population was defined as all screened participants who satisfied all eligibility criteria documented on the eligibility form, entered the study, and had a Year 3 office visit and MRI within the window.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.15" upper_limit="7.24"/>
                    <measurement group_id="O2" value="12.42" lower_limit="4.43" upper_limit="32.13"/>
                    <measurement group_id="O3" value="2.35" lower_limit="0.59" upper_limit="9.08"/>
                    <measurement group_id="O4" value="6.13" lower_limit="1.98" upper_limit="18.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years (followup after implantation that occurred between 07 July 2009 and 01 January 2012)</time_frame>
      <desc>Adverse events were not collected in this study. Deaths are reported as Serious Adverse Events. Specific local complications were collected and are reported in the Outcome Measure section. Evaluable population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Augmentation</title>
          <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="E2">
          <title>Reconstruction</title>
          <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="E3">
          <title>Revision-Augmentation</title>
          <description>Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="E4">
          <title>Revision-Reconstruction</title>
          <description>Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>Following knee surgery</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area, Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

